-
Product Insights
NewMesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely,...
-
Product Insights
NewLiposarcoma – Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
-
Product Insights
NewMesenchymal Tumor – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors are tumors developing from mesenchymal tissues. These tissues are made of cells including fibroblasts, nerve cells, blood vessel cells, muscle cells, and others. Benign soft tissue tumors are common in humans, but cancerous mesenchymal tumors are rare. Many tumors can originate from various cells, and the treatment mainly depends on the tumor's type, severity, and aggressiveness. These are soft tissue...
-
Product Insights
NewNon-Rhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Non-Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common...
-
Product Insights
NewTransitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024
Empower your strategies with our Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024 report and make more profitable business decisions. Transitional cell carcinoma (TCC), also known asurothelial cell carcinoma, is a type of cancer that primarily affects the transitional epithelial cells lining the urinary tract, including the bladder, ureters, and renal pelvis. It is the most common form of bladder cancer. TCC arises when these cells undergo malignant changes, often due to exposure to carcinogens like tobacco or...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in High-Grade Glioma Drug Details: Cemiplimab (Libtayo) is an anti-neoplastic agent. It is formulated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PPMX-T002 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PPMX-T002 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PPMX-T002 in Fallopian Tube Cancer Drug Details: PPMX-T002 (FF-21101) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – interferon gamma-1b in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - interferon gamma-1b in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon gamma-1b in Ovarian Cancer Drug Details: Human interferon gamma-1b...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – interferon gamma-1b in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - interferon gamma-1b in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon gamma-1b in Non-Small Cell Lung Cancer Drug...